Jamison Private Wealth Management Inc. Acquires 1,521 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Jamison Private Wealth Management Inc. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 27,957 shares of the biopharmaceutical company’s stock after purchasing an additional 1,521 shares during the period. Jamison Private Wealth Management Inc.’s holdings in Gilead Sciences were worth $2,582,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. FMR LLC raised its position in shares of Gilead Sciences by 79.4% during the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after acquiring an additional 14,680,161 shares during the last quarter. Wellington Management Group LLP increased its position in Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after purchasing an additional 11,665,593 shares during the period. Point72 Asset Management L.P. raised its holdings in Gilead Sciences by 350.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock worth $193,274,000 after purchasing an additional 1,793,145 shares during the last quarter. International Assets Investment Management LLC lifted its position in shares of Gilead Sciences by 8,238.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock worth $137,708,000 after purchasing an additional 1,622,806 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Gilead Sciences by 159.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,337,717 shares of the biopharmaceutical company’s stock valued at $195,994,000 after purchasing an additional 1,437,842 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 target price on the stock. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Wolfe Research assumed coverage on Gilead Sciences in a research report on Friday, November 15th. They set an “outperform” rating and a $110.00 target price on the stock. Piper Sandler lifted their target price on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $97.96.

Insider Transactions at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares in the company, valued at $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock worth $42,130,461 in the last quarter. Insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 0.2 %

Shares of GILD stock opened at $93.07 on Friday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The company has a market capitalization of $115.99 billion, a price-to-earnings ratio of 1,034.11, a PEG ratio of 1.31 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90. The company has a 50-day simple moving average of $91.74 and a two-hundred day simple moving average of $84.86.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s revenue was up 7.0% compared to the same quarter last year. During the same period last year, the firm posted $2.29 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.